University of Oxford Initiates Human Trials for New Bundibugyo Ebola Vaccine Amid Regional Outbreaks

Scientists at the University of Oxford have officially launched the first human clinical trial for a vaccine designed to combat the Bundibugyo ebolavirus (BDBV). The trial, designated as BD-Ebov, comes at a critical time as the Democratic Republic of the Congo (DRC) and Uganda continue to face threats from various Ebola strains, with the DRC alone reporting approximately 625 fatalities in recent outbreaks. This new vaccine is the first of four currently under development by the Oxford team to receive regulatory approval in the UK, signaling a significant milestone in the global effort to curb the spread of this deadly disease.

The early-stage trial is being conducted in the United Kingdom with 50 healthy adult volunteers aged 18 to 55. Researchers will primarily assess the vaccine's safety and its ability to provoke a robust immune response in humans. Developed in a remarkably short timeframe of just eight weeks, the ChAdOx1 BDBV vaccine utilizes the same adenovirus vector technology that underpinned the successful Oxford/AstraZeneca COVID-19 vaccine. This approach uses a modified, harmless virus to deliver genetic instructions to the immune system, a method that has proven to be both scalable and effective during previous global health emergencies.

Beyond the initial clinical trials in Oxford, the research team is preparing for broader international implementation. Approximately 620,000 doses of the vaccine have already been produced in anticipation of positive trial results and future deployment. Plans are also underway to initiate clinical trials within Africa, specifically in regions where conflict and geographic challenges have historically hindered outbreak response efforts. While other pharmaceutical entities, such as Moderna, are also exploring Ebola vaccines using mRNA technology, the Oxford team’s rapid development and existing manufacturing capacity position this candidate as a vital tool in the international health security arsenal.